Data presented at the 14th International Congress on Autoimmunity
Encouraging preclinical data observed to date on par with OFEV® (nintedanib),
a leading tyrosine kinase inhibitor with 2025 projected sales of $5 billion1
Company targeting IND filing for GRI-0803 in Q3 2024 with topline data expected Q4 2024